Shares of Enlivex Therapeutics Ltd. (NASDAQ:ENLV) were down 0.2% on Tuesday . The company traded as low as $4.85 and last traded at $6.06, approximately 100,400 shares were traded during trading. A decline of 24% from the average daily volume of 132,012 shares. The stock had previously closed at $6.07.
A number of research analysts recently weighed in on ENLV shares. Zacks Investment Research lowered Enlivex Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, June 4th. HC Wainwright reissued a “buy” rating on shares of Enlivex Therapeutics in a report on Friday, May 8th.
The firm has a market capitalization of $82.85 million, a price-to-earnings ratio of -8.42 and a beta of 1.83. The company has a fifty day moving average of $5.52.
Enlivex Therapeutics (NASDAQ:ENLV) last released its quarterly earnings results on Monday, May 18th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.17. As a group, analysts anticipate that Enlivex Therapeutics Ltd. will post -1 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ENLV. Renaissance Technologies LLC boosted its stake in Enlivex Therapeutics by 61.4% in the 4th quarter. Renaissance Technologies LLC now owns 38,390 shares of the company’s stock valued at $322,000 after purchasing an additional 14,600 shares during the period. Morgan Stanley boosted its stake in Enlivex Therapeutics by 1,407,350.0% in the 1st quarter. Morgan Stanley now owns 28,149 shares of the company’s stock valued at $132,000 after purchasing an additional 28,147 shares during the period. Finally, Sabby Management LLC bought a new stake in Enlivex Therapeutics in the 1st quarter valued at $2,086,000. Institutional investors and hedge funds own 7.15% of the company’s stock.
About Enlivex Therapeutics (NASDAQ:ENLV)
Enlivex Therapeutics Ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. Its product candidate is Allocetra, an immunotherapy candidate for the prevention of complications post bone marrow transplantations; treatment of patients that do not respond to steroid treatment upon occurrence of graft vs host disease post bone marrow transplantations; and prevention of cytokine storms, organ damage, and multiple organ failure in sepsis patients.
Receive News & Ratings for Enlivex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enlivex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.